ClinicalTrials.gg
RecruitingNCT02185443Updated Dec 9, 2024

Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases

A Phase 2 interventional study of SBRT in Liver Metastases, Colorectal Cancer and Anal Canal Cancer, sponsored by University of Sao Paulo. Recruiting at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by University of Sao Paulo · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 79 studies in Colorectal Neoplasms with a site in Brazil — 18 open to participants now, 27 under way, 12 of them phase 3. Colorectal Neoplasms · Brazil.

Planned enrollment
64th of 71
43 · median 392
Started
2014
with 1 other
Phase 2
15 of 79
2 open now
Primary completion
2026-12
later than 5 of 26 live
Registered
32nd of 79
by date
Lead sponsor
3 of 79
University of Sao Paulo

Among the 79 studies in Colorectal Neoplasms with a site in Brazil, this one is the 64th largest by planned enrollment of the 71 interventional ones that give a count, is one of 2 that started in 2014, is one of 15 in phase 2, reaches primary completion later than 5 of the 26 other live ones, and was the 32nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

18 of the 79 studies in Colorectal Neoplasms with a site in Brazil are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 79 studies in Colorectal Neoplasms with a site in Brazil, or all of them as a file.
02

Study summary

This is a Phase II study to determine the efficacy of SBRT to treat liver metastases in patients with Colorectal Adenocarcinoma, Carcinoma of the Anal Canal and Gastrointestinal Neuroendocrine Tumors that are not amenable to surgery. Patients should have no evidence of extra-hepatic disease or have disease that is planned to be treated with curative intent.

Therefore, SBRT is being considered as a potentially curative procedure.

03

Conditions studied

  • Liver Metastases
  • Colorectal Cancer
  • Anal Canal Cancer
  • Gastrointestinal Neuroendocrine Tumors

Keywords

  • SBRT
  • radiation
  • Neoplasm Metastasis
  • Colorectal Neoplasms
  • Anal Canal
  • Neuroendocrine Tumors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Performance Scale (KPS) equal or greater than 70
  • 1 to 4 liver with an individual maximum diameter of up to 5 cm
  • Lesions considered unresectable or patients considered unfit for surgery
  • Histology of the primary tumor: colorectal adenocarcinoma, carcinoma of the anal canal or gastrointestinal neuroendocrine tumors.
  • Absence of evidence of extra-hepatic disease or extra-hepatic disease to be treated with curative intent.
  • Minimum interval of 2 weeks between systemic chemotherapy and SBRT.
  • Adequate bone marrow function defined as:
  • absolute neutrophils count > 1,800 cells / mm 3
  • > 100,000 cells / mm 3
  • > 8.0 g / dl ( transfusion or other intervention accepted)

Exclusion criteria

Exclusion Criteria:

  • Concomitant chemotherapy
  • Prior radiotherapy to the upper abdomen
  • Pregnancy
  • Underlying Cirrhosis
  • Active hepatitis or liver failure
  • Prior invasive neoplasm except for non-melanoma skin cancer, or unless more than five years without evidence of disease
  • Severe Comorbidity
  • Current anticoagulant treatment
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (estimated)

Study arms

  • Experimental
    SBRT

    Radiation: SBRT

Interventions

  • RadiationSBRT

    * 60Gy in 3 fractions (20Gy/fraction) over 14 days * 60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above

    Also known as: Stereotactic Body Radiation Therapy

06

What researchers measure

Primary outcomes

  1. Local Progression Free Survival

    - Local Progression Free Survival of treated lesions in evaluable patients. Local Progression Free Survival will be defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria applied to the Planning Target Volume (PTV) and 1cm around (assessment of marginal failure). Time-to-events will be counted from the date of initiation of treatment. Patients will be considered evaluable if followed for at least 6 months after SBRT. A review after 6 months is due to the transient changes after irradiation that make uncertain radiological evaluation before 6 months.

    Time frame: 2 years

Secondary outcomes

  1. Overall Survival

    Time frame: 5 years

  2. Progression Free Survival

    Time frame: 5 years

  3. Toxicity

    treatment related toxicity evaluated by the Common Toxicity Criteria for Adverse Effects (CTCAE) v. 4

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • Instituto do Cancer do Estado de São Paulo
    São Paulo, SP 01246-000, Brazil
    Recruiting
    • Andre TC Chen, MD · Contactandre.chen@hc.fm.usp.br · 55-11-3893-4540
    • Karina Moutinho, MD · Sub investigator
    • Rachel Riechelman, MD, PhD · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2014, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 9, 2014
Start
May 2014
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02185443
Collaborators
Instituto do Cancer do Estado de São Paulo
Responsible party
Andre Tsin Chih Chen (MD, PhD, University of Sao Paulo) — Principal investigator
First posted
Jul 9, 2014
Start date
May 2014
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Dec 9, 2024

Study contacts

Andre TC Chen, MD, PhD
Contact
andre.chen@hc.fm.usp.br
55-11- 3893-4540
Karina Moutinho, MD
Contact
kamoutinho@gmail.com
55-11-3893-4542
Andre TC Chen, MD, PhD
principal investigator · Instituto do Cancer do Estado de Sao Paulo

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion